Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study

Inclusion Criteria: * Patient over 18 years * Inpatient orthopedic surgery * Achieved a bone and joint infection documented gram + (staphylococci golden coagulase-negative staphylococci, enterococci, streptococci) * Bacteria resistant to lincosamides, quinolones and rifampicin * Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L) * Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL) Exclusion Criteria: * Patient not affiliated to the social security * Pregnant and lactating women * Known hypersensitivity to teicoplanin (rash, ...) * Patients with a central catheter or an implantable chamber * Patient hemodialysis * Patient has another participant biomedical research on a drug to prevent drug interactions * Patient minor * Patient major protected (protection of the court, wardship, trusteeship) * Patient admitted for emergency or incapable of consent